病毒学报

参考文献

[1] Li Q,Liu Q,Huang W,Li X,Wang Y. Current status on the development of pseudoviruses for enveloped viruses[J]. Rev Med Virol,2018,28(1).

[2] Pasloske B L,Walkerpeach C R,Obermoeller R D,Winkler M,DuBois D B. Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards[J]. J Clin Microbiol,1998,36(12):3590-3594.

[3] Chan J F,Kok K H,Zhu Z,Chu H,To K K,Yuan S,Yuen K Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerg Microbes Infect,2020,9(1):221-236.

[4] Zhou P,Yang X-L,Wang X-G,Hu B,Zhang L,Zhang W,Si H-R,Zhu Y,Li B,Huang C-L,Chen HD,Chen J,Luo Y,Guo H,Jiang R-D,Liu M-Q,Chen Y,Shen X-R,Wang X,Zheng X-S,Zhao K,Chen Q-J,Deng F,Liu L-L,Yan B,Zhan F-X,Wang Y-Y,Xiao G-F,Shi Z-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature,2020.

[5] Letko M,Marzi A,Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses[J]. Nat Microbiol,2020.

[6] Lu H,Ai J,Shen Y,Li Y,Li T,Zhou X,Zhang H,Zhang Q,Ling Y,Wang S,Qu H,Gao Y,Li Y,Yu K,Zhu D,Zhu H,Tian R,Zeng M,Li Q,Song Y,Li X,Xu J,Xu J,Mao E,Hu B,Li X,Zhu L,Zhang W.A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai,lessons learned for metropolis epidemics prevention[J].medRxiv,2020:2020.2002.2019.20025031.

[7] Ansarah-Sobrinho C,Nelson S,Jost C A,Whitehead S S,Pierson T C. Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation[J]. Virology,2008,381(1):67-74.

[8] Chen P,Song Z,Qi Y,Feng X,Xu N,Sun Y,Wu X,Yao X,Mao Q,Li X,Dong W,Wan X,Huang N,Shen X,Liang Z,Li W. Molecular determinants of enterovirus 71 viral entry:cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2[J]. J Biol Chem,2012,287(9):6406-6420.

[9] Ma J,Chen R,Huang W,Nie J,Liu Q,Wang Y,Yang X. In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus[J]. Hum Vaccin Immunother,2019,15(10):2286-2294.

[10]Nie J,Huang W,Wu X,Wang Y. Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus(HPV)based on pseudovirons[J]. J Med Virol,2014,86(9):1542-1555.

[11]Sarzotti-Kelsoe M,Bailer R T,Turk E,Lin C L,Bilska M,Greene K M,Gao H,Todd C A,Ozaki D A, Seaman M S, Mascola J R, Montefiori D C.Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1[J]. J Immunol Methods,2014,409:131-146.

[12]Carnell G W,Ferrara F,Grehan K,Thompson C P,Temperton N J. Pseudotype-based neutralization assays for influenza:a systematic analysis[J]. Front Immunol,2015,6:161.

[13]WalkerPeach C R,Winkler M,DuBois D B,Pasloske B L. Ribonuclease-resistant RNA controls(Armored RNA)for reverse transcription-PCR,branched DNA,and genotyping assays for hepatitis C virus[J]. Clin Chem,1999,45(12):2079-2085.

[14]Mattiuzzo G,Ashall J,Doris K S,MacLellan-Gibson K,Nicolson C,Wilkinson D E,Harvey R,Almond N,Anderson R, Efstathiou S, Minor P D, Page M.Development of lentivirus-based reference materials for Ebola virus nucleic acid amplification technology-based assays[J/OL]. PLoS One,2015,10(11):e0142751.

[15]Krajden M,Cook D,Yu A,Chow R,Su Q,Mei W,McNeil S, Money D, Dionne M, Palefsky J,Karunakaran K,Kollmann T,Ogilvie G,Petric M,Dobson S. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial[J]. Vaccine,2014,32(5):624-630.

[16]Krajden M,Cook D,Yu A,Chow R,Mei W,McNeil S,Money D,Dionne M,Karunakaran K P,Palefsky J M, Dobson S, Ogilvie G, Petric M. Human papillomavirus 16(HPV 16)and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two-versus three-dose HPV vaccine trial[J]. Clin Vaccine Immunol,2011,18(3):418-423.

[17]王佑春，聂建辉，吴雪伶，刘强.假病毒检测平台的建立以及应用[J].中华微生物学和免疫学杂志，2013,33(1):40-46.

[18]Nie J, Huang W, Liu Q, Wang Y. HIV-1pseudoviruses constructed in China regulatory laboratory[J]. Emerg Microbes Infect,2020,9(1):32-41.

[19]Laher F, Moodie Z, Cohen K W, Grunenberg N,Bekker L G,Allen M,Frahm N,Yates N L,Morris L, Malahleha M, Mngadi K, Daniels B, Innes C,Saunders K,Grant S,Yu C,Gilbert P B,Phogat S,DiazGranados C A,Koutsoukos M,Van Der Meeren O,Bentley C,Mkhize N N,Pensiero M N,Mehra V L,Kublin J G,Corey L,Montefiori D C,Gray G E,McElrath M J, Tomaras G D. Safety and immune responses after a 12-month booster in healthy HIVuninfected adults in HVTN 100 in South Africa:A randomized double-blind placebo-controlled trial of ALVAC-HIV(vCP2438)and bivalent subtype C gp120/MF59 vaccines[J/OL]. PLoS Med,2020,17(2):e1003038.

[20]Garcia F, Bernaldo de Quiros J C, Gomez C E,Perdiguero B,Najera J L,Jimenez V,Garcia-Arriaza J,Guardo A C,Perez I,Diaz-Brito V,Conde M S,Gonzalez N,Alvarez A,Alcami J,Jimenez J L,Pich J,Arnaiz J A,Maleno M J,Leon A,Munoz-Fernandez M A,Liljestrom P,Weber J,Pantaleo G,Gatell J M,Plana M,Esteban M. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env,Gag,Pol and Nef proteins of HIV-1subtype B(MVA-B)in healthy HIV-1-uninfected volunteers:A phase I clinical trial(RISVAC02)[J].Vaccine,2011,29(46):8309-8316.

[21]Alberini I,Del Tordello E,Fasolo A,Temperton N J,Galli G, Gentile C, Montomoli E, Hilbert A K,Banzhoff A,Del Giudice G,Donnelly J J,Rappuoli R,Capecchi B. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1influenza viruses[J]. Vaccine,2009,27(43):5998-6003.

[22]Trombetta C M,Perini D,Mather S,Temperton N,Montomoli E. Overview of serological techniques for influenza vaccine evaluation:Past,present and future[J]. Vaccines(Basel),2014,2(4):707-734.

[23]Wu X,Mao Q,Yao X,Chen P,Chen X,Shao J,Gao F,Yu X,Zhu F,Li R,Li W,Liang Z,Wang J,Lu F.Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71[J/OL]. PLoS One,2013,8(6):e64116.

[24]Yan K X,Tan W J,Zhang X M,Wang H J,Li Y,Ruan L. Development and application of a safe SARSCoV neutralization assay based on lentiviral vectors pseudotyped with SARS-CoV spike protein[J]. Bing Du Xue Bao,2007,23(6):440-446.

[25]马建，贺鹏飞，赵晨燕，陈瑞峰，刘强，王佑春，黄维金，杨晓明. SARS和MERS中和抗体假病毒检测方法的建立[J].病毒学报，2019,35(2):189-195.

[26]Millet J K,Tang T,Nathan L,Jaimes J A,Hsu H L,Daniel S,Whittaker G R. Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting[J]. J Vis Exp,2019(145).

[27]Pastrana D V,Buck C B,Pang Y Y,Thompson C D,Castle P E,FitzGerald P C,Kruger Kjaer S,Lowy D R,Schiller J T. Reactivity of human sera in a sensitive,high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18[J].Virology,2004,321(2):205-216.

[28]Nie J,Liu Y,Huang W,Wang Y. Development of a triple-color pseudovirion-based assay to detect neutralizing antibodies against human papillomavirus[J].Viruses,2016,8(4):107.

[29]Ferguson M,Wilkinson D E,Heath A,Matejtschuk P.The first international standard for antibodies to HPV 16[J]. Vaccine,2011,29(38):6520-6526.

[30]Faust H, Eklund C, Sukvirach S, Ngamkham J,Dillner J. Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels[J]. J Clin Virol,2016,78:89-92.

[31]Montefiori D C. Measuring HIV neutralization in a luciferase reporter gene assay[J]. Methods Mol Biol,2009,485:395-405.

[32]Andersen T K,Zhou F,Cox R,Bogen B,Grodeland G. A DNA vaccine that targets hemagglutinin to antigenpresenting cells protects mice against H7 influenza[J]. J Virol,2017,91(23).

[33]Tsai C,Caillet C,Hu H,Zhou F,Ding H,Zhang G,Zhou B,Wang S,Lu S,Buchy P,Deubel V,Vogel F R, Zhou P. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase[J]. Vaccine,2009,27(48):6777-6790.

[34]Zhou H,Huang Y,Yuan S,Li Y,Wu S,Xu J,Huang R. Sequential immunization with consensus influenza hemagglutinins raises cross-reactive neutralizing antibodies against various heterologous HA strains[J].Vaccine,2017,35(2):305-312.

[35]Molesti E,Wright E,Terregino C,Rahman R,Cattoli G,Temperton N J. Multiplex evaluation of influenza neutralizing antibodies with potential applicability to infield serological studies[J]. J Immunol Res, 2014,2014:457932.

[36]Nie J,Li Q,Wu J,Hao H,Zhao C,Liu H,Zhang L,Nie L,Qin H,Lu Q,Li X,Liu J,Fan C,Huang W,Xu M, Wang Y. Establishment and validation of a pseudo-virus neutralization assay for SARS-CoV-2[J].Emerg Microbes Infect,2020,9(1):680-686.

[37]Zhou S,Liu Q,Wu X,Chen P,Wu X,Guo Y,Liu S,Liang Z,Fan C,Wang Y. A safe and sensitive enterovirus A71 infection model based on human SCARB2 knock-in mice[J]. Vaccine,2016,34(24):2729-2736.

[38]Nie J,Wu X,Ma J,Cao S,Huang W,Liu Q,Li X,Li Y,Wang Y. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system[J]. Sci Rep,2017,7:42769.

[39]Li Q,Liu Q,Huang W,Wu J,Nie J,Wang M,Zhao C,Zhang L,Wang Y. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions[J].Vaccine,2017,35(38):5172-5178.

[40]Liu Q,Fan C,Li Q,Zhou S,Huang W,Wang L,Sun C,Wang M,Wu X,Ma J,Li B,Xie L,Wang Y.Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection[J]. Sci Rep,2017,7:45552.

[41]Zhang L,Li Q,Liu Q,Huang W,Nie J,Wang Y. A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system[J]. Hum Vaccin Immunother,2017,13(8):1811-1817.

[42]Nie J,Liu L,Wang Q,Chen R,Ning T,Liu Q,Huang W,Wang Y. Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities[J]. Emerg Microbes Infect,2019,8(1):272-281.

[43]Wu J, Zhao C, Liu Q, Huang W, Wang Y.Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system[J]. Vaccine,2017,35(47):6387-6394.

[44]Fan C,Wu X,Liu Q,Li Q,Liu S,Lu J,Yang Y,Cao Y,Huang W,Liang C,Ying T,Jiang S,Wang Y. A human DPP4-knockin mouse′s susceptibility to infection by authentic and pseudotyped MERS-CoV[J].Viruses,2018,10(9).

[45]Li K,Wohlford-Lenane C L,Channappanavar R,Park J E,Earnest J T,Bair T B,Bates A M,Brogden K A,Flaherty H A,Gallagher T,Meyerholz D K,Perlman S,McCray P B,Jr. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice[J/OL]. Proc Natl Acad Sci U S A,2017,114(15):E3119-E3128.

[46]Hoffmann M,Kleine-Weber H,Krüger N,Müller M,Drosten C,P?hlmann S. The novel coronavirus 2019(2019-nCoV)uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells[J]. bioRxiv,2020:2020.2001.2031.929042.

[47]Linlin Bao W D,Baoying Huang,Hong Gao,Jiangning Liu,Lili Ren,Qiang Wei,Pin Yu,Yanfeng Xu,Feifei Qi,Yajin Qu,Fengdi Li,Qi Lv,Wenling Wang,Jing Xue, Shuran Gong, Mingya Liu, Guanpeng Wang,Shunyi Wang,Zhiqi Song,Linna Zhao,Peipei Liu,Li Zhao,Fei Ye,Huijuan Wang,Weimin Zhou,Na Zhu,Wei Zhen,Haisheng Yu,Xiaojuan Zhang,Li Guo,Lan Chen, Conghui Wang, Ying Wang, Xinmin Wang,Yan Xiao,Qiangming Sun,Hongqi Liu,Fanli Zhu,Chunxia Ma,Lingmei Yan,Mengli Yang,Jun Han,Wenbo Xu, Wenjie Tan, Xiaozhong Peng, Qi Jin,Guizhen Wu,Chuan Qin. The pathogenicity of SARSCoV-2 in hACE2 transgenic mice[J]. bioRxiv,2020.

[48]杨晓明，侯继峰.康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景[J].中国生物制品学杂志. https：//doi.org/10.13200/j.cnki.cjb.002999.

[49]Wright E,Temperton N J,Marston D A,McElhinney L M,Fooks A R,Weiss R A. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes:a cross-species comparison[J]. J Gen Virol,2008,89(Pt 9):2204-2213.

[50]Wright E, McNabb S, Goddard T, Horton D L,Lembo T,Nel L H,Weiss R A,Cleaveland S,Fooks A R. A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa[J]. Vaccine,2009,27(51):7178-7186.

[51]中国研究型医院学会危重医学专业委员会，中国研究型医院学会危重医学专委会青年委员会.重型和危重型新型冠状病毒肺炎诊断和治疗专家共识[J].中华危重病急救医学，2020(2):E011-E011.

[52]Almasaud A,Alharbi N K,Hashem A M. Generation of MERS-CoV pseudotyped viral particles for the evaluation of neutralizing antibodies in mammalian sera[J]. Methods Mol Biol,2020,2099:117-126.

[53]Goo J,Jeong Y,Park Y S,Yang E,Jung D I,Rho S,Park U,Sung H,Park P G,Choi J A,Seo S H,Cho N H, Lee H, Lee J M, Kim J O, Song M.Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein[J]. Virus Res,2020,278:197863.

[54]Cote M,Misasi J,Ren T,Bruchez A,Lee K,Filone C M, Hensley L, Li Q, Ory D, Chandran K,Cunningham J. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection[J].Nature,2011,477(7364):344-348.

[55]Barouch D H,Whitney J B,Moldt B,Klein F,Oliveira T Y,Liu J,Stephenson K E,Chang H W,Shekhar K,Gupta S,Nkolola J P,Seaman M S,Smith K M,Borducchi E N,Cabral C,Smith J Y,Blackmore S,Sanisetty S,Perry J R,Beck M,Lewis M G,Rinaldi W,Chakraborty A K,Poignard P,Nussenzweig M C,Burton D R. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys[J]. Nature,2013,503(7475):224-228.

[56]Sajadi M M,Dashti A,Rikhtegaran Tehrani Z,Tolbert W D,Seaman M S,Ouyang X,Gohain N,Pazgier M,Kim D,Cavet G,Yared J,Redfield R R,Lewis G K,DeVico A L. Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses[J/OL]. Cell,2018,173(7):1783-1795 e1714.

[57]Nyakatura E K, Frei J C, Lai J R. Chemical and structural aspects of Ebola virus entry inhibitors[J].ACS Infect Dis,2015,1(1):42-52.

[58]Zhang X,Liu Q,Zhang N,Li Q Q,Liu Z D,Li Y H,Gao L M, Wang Y C, Deng H B, Song D Q.Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage[J].Eur J Med Chem,2018,149:45-55.

[59]Zhang X,Liu Q,Li Q,Li Y,Liu Z,Deng H,Tang S,Wang Y,Wang Y,Song D. Synthesis and biological evaluation of novel tricyclic matrinic derivatives as potential anti-filovirus agents[J]. Acta Pharm Sin B,2018,8(4):629-638.

[60]Zhang X, Tang K, Guo Y. The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein[J]. Antiviral Res, 2020, 174:104701.

[61]Xu L,Zhang T,Xu X,Chong H,Lai W,Jiang X,Wang C,He Y,Liu K. DNA triplex-based complexes display anti-HIV-1-cell fusion activity[J]. Nucleic Acid Ther,2015,25(4):219-225.

[62]Chong H, Zhu Y, Yu D, He Y. Structural and functional characterization of membrane fusion inhibitors with extremely potent activity against human immunodeficiency virus type 1(HIV-1),HIV-2,and simian immunodeficiency virus[J]. J Virol, 2018,92(20).

[63]Xiong S,Borrego P,Ding X,Zhu Y,Martins A,Chong H,Taveira N,He Y. A helical short-peptide fusion inhibitor with highly potent activity against human immunodeficiency virus type 1(HIV-1),HIV-2,and simian immunodeficiency virus[J]. J Virol,2017,91(1).

[64]Zhao G,Du L,Ma C,Li Y,Li L,Poon V K,Wang L,Yu F,Zheng B J,Jiang S,Zhou Y. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERSCoV[J]. Virol J,2013,10:266.

[65]Kato S,Kobayashi K,Inoue K,Kuramochi M,Okada T,Yaginuma H,Morimoto K,Shimada T,Takada M,Kobayashi K. A lentiviral strategy for highly efficient retrograde gene transfer by pseudotyping with fusion envelope glycoprotein[J]. Hum Gene Ther,2011,22(2):197-206.

[66]Li F,Li W,Farzan M,Harrison S C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor[J]. Science, 2005, 309(5742):1864-1868.

[67]Li W,Moore M J,Vasilieva N,Sui J,Wong S K,Berne M A,Somasundaran M,Sullivan J L,Luzuriaga K,Greenough T C,Choe H,Farzan M. Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature,2003,426(6965):450-454.

[68]Zhang D,Lin G,Yi L,Hao M,Fan G,Yang X,Peng R,Ding J,Zhang K,Zhang R,Li J. External quality assessment for rubella virus RNA detection using armored RNA in China[J]. Clin Lab,2017,63(2):399-405.

[69]Yao L,Li F,Qu M,Guo Y,Jiang Y,Wang L,Zhai Y. Development and evaluation of a novel armored RNA technology using bacteriophage Qβ[J]. Food Environ Virol,2019,11(4):383-392.

[70]Sun Y,Jia T,Sun Y,Han Y,Wang L,Zhang R,Zhang K, Lin G, Xie J, Li J. External quality assessment for Avian Influenza A(H7N9)Virus detection using armored RNA[J]. J Clin Microbiol,2013,51(12):4055-4059.

[71]Hietala S K,Crossley B M. Armored RNA as virus surrogate in a real-time reverse transcriptase PCR assay proficiency panel[J]. J Clin Microbiol,2006,44(1):67-70.

[72]Goldmeyer J,Kong H,Tang W. Development of a novel one-tube isothermal reverse transcription thermophilic helicase-dependent amplification platform for rapid RNA detection[J]. J Mol Diagn,2007,9(5):639-644.

[73]Dedkov V G, Magassouba N, Safonova M V,Naydenova E V, Ayginin A A, Soropogui B,Kourouma F,Camara A B,Camara J,Kritzkiy A A,Tuchkov I V, Shchelkanov M Y, Maleev V V.Development and evaluation of a one-step quantitative RT-PCR assay for detection of Lassa virus[J]. J Virol Methods,2019,271:113674.

[74]周冬根，李云鹏，罗洁，李军花，余军平，危宏平.用于MERS-CoV核酸检测的假病毒阳性对照品制备及鉴定[J].中国国境卫生检疫杂志，2019,42(4):233-239.

[75]Cheng Y,Niu J,Zhang Y,Huang J,Li Q. Preparation of His-tagged armored RNA phage particles as a control for real-time reverse transcription-PCR detection of severe acute respiratory syndrome coronavirus[J]. J Clin Microbiol,2006,44(10):3557-3561.

[76]Zhan S,Li J,Xu R,Wang L,Zhang K,Zhang R.Armored long RNA controls or standards for branched DNA assay for detection of human immunodeficiency virus type 1[J]. J Clin Microbiol,2009,47(8):2571-2576.

[77]莫茜，秦炜，傅启华，关明.正确认识新冠病毒核酸检测的影响因素[J].中华检验医学杂志，2020(00):E002-E002.

[78]张瑞，李金明.如何减少新型冠状病毒核酸检测的"假阴性"[J].中华医学杂志，2020(00):E008-E008.

[79]王成彬.核酸检测用于确诊新型冠状病毒肺炎阳性率低的原因分析[J].中华医学杂志，2020(00):E010-E010.